Organogenesis COO reports tax-related share disposals

Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported several insider transactions involving Class A common stock.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported several insider transactions involving Class A common stock. On February 15, 2026, he disposed of shares in four separate transactions coded “F,” which indicates shares were delivered to cover a tax liability or exercise price.

Across these tax-withholding dispositions, shares were transferred at a reported price of $3.73 per share. After the final transaction, Bilbo continued to directly own 884,648 shares of Class A common stock, reflecting a substantial remaining equity stake in the company.

Insider Trade Summary

Exercise Price or Tax Liability: 64,414 shares

Exercise Price or Tax Liability 4 txns

Insider Bilbo Patrick

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	5,114	$3.73	$19K
Exercise Price or Tax Liability	Class A Common Stock	28,331	$3.73	$106K
Exercise Price or Tax Liability	Class A Common Stock	15,617	$3.73	$58K
Exercise Price or Tax Liability	Class A Common Stock	15,352	$3.73	$57K

Holdings After Transaction: Class A Common Stock — 884,648 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORGO’s COO report on this Form 4?

Organogenesis COO Patrick Bilbo reported multiple Form 4 transactions disposing of Class A common stock. All were coded “F,” meaning shares were delivered to satisfy tax liabilities or exercise prices rather than open-market sales, and they occurred on February 15, 2026.

How many Organogenesis (ORGO) shares did the COO dispose of for taxes?

Patrick Bilbo reported four tax-withholding dispositions of Class A common stock at $3.73 per share. Each transaction reflects shares delivered to cover obligations, rather than traditional market sales, as indicated by the Form 4 transaction code “F” and description provided.

What was the transaction price per share in the ORGO insider filing?

Each reported disposition of Organogenesis Class A common stock by COO Patrick Bilbo was priced at $3.73 per share. This consistent price applies across the February 15, 2026 tax-withholding transactions coded “F” on the Form 4 insider trading report.

How many Organogenesis (ORGO) shares does the COO own after these transactions?

Following the final February 15, 2026 transaction, COO Patrick Bilbo directly owns 884,648 shares of Organogenesis Class A common stock. This figure reflects his remaining stake after delivering shares to cover tax liabilities or exercise-price obligations under the Form 4 filing.

Are the ORGO COO’s Form 4 transactions open-market stock sales?

No, the transactions are coded “F,” meaning they represent payment of exercise price or tax liability by delivering securities. These are tax-withholding dispositions, not discretionary open-market stock sales, according to the transaction code description in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bilbo Patrick

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/15/2026		F		5,114	D	$3.73	943,948	D
Class A Common Stock	02/15/2026		F		28,331	D	$3.73	915,617	D
Class A Common Stock	02/15/2026		F		15,617	D	$3.73	900,000	D
Class A Common Stock	02/15/2026		F		15,352	D	$3.73	884,648	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stacie S. Aarestad, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.